Skip to main content

Table 3 Comparison of characteristics between BM+ patients on 30 mg and 40 mg starting dose. Comparing the clinical characteristics of patients with brain metastases who started on 30 mg OD vs 40 mg OD of afatinib

From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Characteristic Starting dose 30 mg,
n (%)
Starting dose 40 mg,
n (%)
p-value
Age at diagnosis, years
 Median (range) 62 (47–78) 58 (26–76) 0.299
  < 65 15 (60.0) 12 (70.6) 0.482
  ≥ 65 10 (40.0) 5 (29.4)  
Sex
 Female 16 (64.0) 6 (35.3) 0.067
 Male 9 (36.0) 11 (64.7)  
ECOG at start of afatinib
 0–1 20 (80.0) 14 (82.4) 1.000
 2–3 5 (20.0) 3 (17.6)  
Smoking history
 Never 18 (72.0) 13 (76.5) 1.000
 Former/Current 7 (28.0) 4 (23.5)  
Brain RT pre-afatinib
 Yes 12 (48.0) 14 (82.4) 0.024
 No 13 (52.0) 3 (17.6)  
Brain RT post-afatinib
 Yes 4 (16.0) 3 (17.6) 1.000
 No 21 (84.0) 14 (82.4)  
EGFR mutation type
 Exon 19 deletion 15 (62.5) 9 (52.9) 0.019
 Exon 20 insertion 1 (4.2) 0  
 Exon 21 L858R 3 (12.5) 8 (47.1)  
 Double mutation 5 (20.8) 0  
 Unknown 1 0  
Site of progressiona
 CNS 7 (63.6) 3 (30.0) 0.198
 Systemic 4 (36.4) 7 (70.0)  
 No PD / unknown:    
  Still on afatinib 5 2  
  Went on 2nd line 3 4  
  No scans / no PD recorded 4 1  
  FU at other hospital 2 0  
Afatinib dose at PD, mg
 20 2 (18.2) 1 (10.0) 0.270
 30 9 (81.8) 6 (60.0)  
 40 0 3 (30.0)  
 No PD / unknown 14 7  
  1. Note: Unknown data were not included in the calculation of percentages and p-values
  2. aCNS PD: brain. Systemic PD: lung, bone/spine, liver, mediastinal LN, malignant pericardial effusion, nodes, pleura
  3. bNote that there were 9 patients (5 on 30 mg and 4 on 40 mg) who were still on afatinib at data cut-off. Dose intensity was calculated up to last follow-up date for these patient